Antonio_Diaz/iStock via Getty Images Investment Overview I last covered Phathom Pharmaceuticals (NASDAQ:PHAT) for Seeking Alpha around three and a half years ago, in January 2021, when the biotech's stock traded ~$39 per share, more than double its October 2019 IPO price of $19 per share (the IPO raised >$200m). I wrote as follows: Phathom is a straightforward investment case in many ways. The New Jersey based biotech has in-licensed the rights to Vonoprazan - an oral small molecule potassium competitive a ...